Anghel Larisa, Stătescu Cristian, Șerban Ionela-Lăcrămioara, Mărănducă Minela Aida, Butcovan Doina, Clement Alexandra, Bostan Mădălina, Sascău Radu
Internal Medicine Department, "Grigore T. Popa" University of Medicine and Pharmacy, 700503 Iași, Romania.
Cardiology Department, Cardiovascular Diseases Institute "Prof. Dr. George I.M.Georgescu", 700503 Iași, Romania.
Diagnostics (Basel). 2020 Sep 19;10(9):719. doi: 10.3390/diagnostics10090719.
In recent years, significant advances have been made in the diagnosis and therapeutic management of hypertrophic cardiomyopathy (HCM) patients, which has led to an important improvement in their longevity and quality of life. The use of multimodality imaging has an essential role in the diagnosis, assessing the regional distribution and severity of the disease, with important prognostic implications. At the same time, imaging contributes to the identification of optimal treatment for patients with hypertrophic cardiomyopathy, whether it is pharmaceutical, interventional or surgical treatment. Novel pharmacotherapies (like myosin inhibitors), minimally invasive procedures (such as transcatheter mitral valve repair, high-intensity focused ultrasound or radiofrequency ablation) and gene-directed approaches, may soon become alternatives for HCM patients. However, there are only few data on the early diagnosis of patients with HCM, in order to initiate treatment as soon as possible, to reduce the risk of sudden cardiac death (SCD). The aim of our review is to highlight the advantages of contemporary imaging in choosing the optimal management strategies for HCM patients, considering the novel therapies which are currently applied or studied for these patients.
近年来，肥厚型心肌病（HCM）患者的诊断和治疗管理取得了重大进展，这使其寿命和生活质量得到了显著改善。多模态成像在诊断、评估疾病的区域分布和严重程度方面发挥着重要作用，具有重要的预后意义。同时，成像有助于为肥厚型心肌病患者确定最佳治疗方案，无论是药物治疗、介入治疗还是手术治疗。新型药物疗法（如肌球蛋白抑制剂）、微创手术（如经导管二尖瓣修复、高强度聚焦超声或射频消融）以及基因导向方法，可能很快成为HCM患者的替代治疗选择。然而，关于HCM患者早期诊断的数据很少，以便尽早开始治疗，降低心源性猝死（SCD）的风险。我们综述的目的是强调当代成像在为HCM患者选择最佳管理策略方面的优势，同时考虑目前应用于这些患者或正在研究的新型疗法。
